证券代码：603235 证券简称：天新药业 公告编号：2025-028 江西天新药业股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司将于 2025 年 8 月 29 日发布公司 2025 年半年度报告，为便于广大投资 者更全面深入地了解公司 2025 年半年度的经营成果、财务状况，公司计划于 2025 年 9 月 3 日（星期三）下午 16:00-17:00 举行 2025 年半年度业绩说明会，就投资 者关心的问题进行交流。 一、说明会类型 三、参加人员 董事、总经理：余小兵先生 独立董事：刘桢女士 本次业绩说明会以网络互动形式召开，公司将针对 2025 年半年度的经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围 内就投资者普遍关注的问题进行回答。 会议召开时间：2025 年 9 月 3 日（星期三）下午 16:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ...

证券日报网讯8月15日晚间，天新药业（603235）发布公告称，董事会于2025年8月15日收到公司董事、 副总经理谢涛先生的书面辞职报告。因个人原因，谢涛先生申请辞去公司董事、副总经理职务。 ...

证券代码：603235 证券简称：天新药业 公告编号：2025-027 江西天新药业股份有限公司 关于公司董事、副总经理离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江西天新药业股份有限公司（以下简称"公司"）董事会于 2025 年 8 月 15 日收到公司董事、副总经理谢涛先生的书面辞职报告。因个人原因，谢涛先 生申请辞去公司董事、副总经理职务。具体情况如下： 特此公告。 江西天新药业股份有限公司董事会 2025 年 8 月 16 日 | 姓名 | 离任职务 | 离任时间 | | 原定任期到 | | 离任 | 是否继续在 上市公司及 | 具体 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 期日 | | 原因 | 其控股子公 | 职务 | 毕的公开 | | | | | | | | | 司任职 | | 承诺 | | 谢涛 | 董事、副 | 2025 8 | 年 | 2026 11 | 年 | ...

（文章来源：每日经济新闻） 天新药业（SH 603235，收盘价：28.77元）8月15日晚间发布公告称，公司董事会于2025年8月15日收到 公司董事、副总经理谢涛先生的书面辞职报告。因个人原因，谢涛先生申请辞去公司董事、副总经理职 务。 2024年1至12月份，天新药业的营业收入构成为：营养品占比93.28%，其他占比5.45%，其他业务占比 1.27%。 ...

Group 1 - The company Tianxin Pharmaceutical (603235) stated that its Vitamin D3 business currently represents a small proportion of its overall revenue [1] - Investors are encouraged to monitor the company's periodic reports or related announcements for specific business details [1]

Group 1 - Hengbang Co., Ltd. plans to establish a joint venture with Huasheng Development with a registered capital of 10 million yuan, where Hengbang will contribute 8 million yuan (80%) and Huasheng will contribute 2 million yuan (20%) [1] - Hunan Gold's subsidiary Anhua Zhazi Creek Smelting Plant will undergo temporary maintenance starting from the end of June 2025, expected to last no more than 30 days [2] - Defu Technology's subsidiary signed supply agreements for lithium battery copper foil products with two leading global companies, with contract durations of 3 years and 5 years respectively [3] Group 2 - Binjiang Group won the rights to two residential land parcels for a total price of 4.368 billion yuan [5] - Zhong'an Technology announced the resignation of its executive vice president and board secretary due to personal reasons [7] - Changqing Technology's project for special polymer materials and electronic materials has officially commenced production, adding a capacity of 120,500 tons per year [10] Group 3 - Gansu Energy received approval from the China Securities Regulatory Commission to publicly issue bonds totaling up to 2 billion yuan [10] - Shuoshi Biology obtained a medical device registration certificate for an in vitro diagnostic reagent, valid until June 2030 [12] - Yawen Co., Ltd. plans to issue shares to specific investors, with the application accepted by the Shenzhen Stock Exchange [13] Group 4 - Guoyao Modern's subsidiary received approval for the listing of a raw material drug, which is a selective anticholinergic agent [16] - Inner Mongolia First Machinery's subsidiary signed a railway freight car procurement contract worth 130 million yuan [18] - Xining Special Steel plans to raise up to 1 billion yuan through a private placement to its controlling shareholder [39] Group 5 - Huadong Medicine's subsidiary received approval for a clinical trial of a new injectable drug targeting advanced solid tumors [29] - Warner Pharmaceutical's compound potassium hydrogen phosphate injection passed the consistency evaluation for generic drugs [30] - North Special Technology plans to raise up to 300 million yuan through a private placement for a production base project in Thailand [30] Group 6 - Xiangyang Technology is the first candidate for a 533 million yuan Airbus project [45] - Haishun New Materials intends to acquire 100% of Guangdong Zhengyi Packaging [46] - Jida Zhengyuan's shareholder plans to reduce their stake by up to 0.73% due to personal financial needs [47]

基于对公司未来持续稳定发展的信心以及对公司价值的认可，公司股东厚 鼎投资、厚盛投资、厚泰投资承诺自愿将其所持有的公司首次公开发行前的股 份锁定期，自 2025 年 7 月 11 日锁定期满之日起，延长 6 个月，至 2026 年 1 月 11 日。承诺在上述延长的锁定期内，不转让或委托他人管理所持有的限售股股 份，亦不会要求公司回购该部分股份。若因公司送红股、转增股本、配股等原 因而导致所持股份数量增加，增加的股份同样遵守上述延长锁定期的承诺。待 承诺的锁定期届满后，所持股份的转让和交易将严格依照届时有效的法律、法 规，以及中国证券监督管理委员会、上海证券交易所的有关规定办理。承诺严 格履行上述约定，若违反本承诺，愿意承担由此产生的相应法律责任。 序号 股东名称 持股数量 （股） 持股比例 原股份锁定期 延长后锁定期 1 厚鼎投资 24,000,000 5.48% 2025/7/11 2026/1/11 二、相关股东持有的限售股锁定期延长情况 证券代码：603235 证券简称：天新药业 公告编号：2025-026 江西天新药业股份有限公司 关于股东自愿延长股份锁定期的公告 本公司董事会及全体董事保证本公告内容 ...

Group 1 - The company Tianxin Pharmaceutical (603235) announced that its shareholders, Hou Ding Investment, Hou Sheng Investment, and Hou Tai Investment, voluntarily extended the lock-up period for their shares prior to the company's initial public offering by 6 months, until January 11, 2026 [1] - After the extension of the lock-up period, the restricted shares held by the aforementioned shareholders will be eligible for trading starting from January 12, 2026 [1]

Investment Rating - The investment rating for the company is maintained as "Buy" [2] Core Views - The prices of the main products, Vitamin B1 and B6, remain strong, contributing to profit growth. The company is a significant supplier in the global B vitamin market, holding leading market shares in Vitamin B6 and B1, with a revenue contribution of 78% from B vitamins in 2024. The prices for Vitamin B6 and B1 have shown year-on-year increases of 43.8% and 21.04% respectively in the first half of 2025, driving rapid profit growth [8][5] - The company is expanding its product line with new projects, including Vitamin B5 and Vitamin A, which are expected to enhance its long-term growth potential. The successful launch of these new products could significantly increase the company's market presence [8] - The financial forecast has been slightly adjusted, with expected net profits for 2025, 2026, and 2027 projected at 921 million, 1,063 million, and 1,070 million respectively. The corresponding PE ratios are estimated at 13, 11, and 11 times. The target market value for 2025 is set at 141 billion, indicating a 21% upside potential from the current market value [8][10] Financial Data and Profit Forecast - Total revenue is projected to grow from 2,209 million in 2024 to 2,708 million in 2025, with a year-on-year growth rate of 22.6%. The net profit is expected to increase from 651 million in 2024 to 921 million in 2025, reflecting a growth rate of 41.4% [7][12] - The gross margin is anticipated to improve from 42% in 2024 to 51.1% in 2025, while the return on equity (ROE) is expected to rise from 14.1% to 16.6% during the same period [7][12]

关于江西天新药业股份有限公司 2024 年度利润分配涉及的差异化分红事项的 法律意见书 二〇二五年五月 北京市中伦（上海）律师事务所 北京市中伦（上海）律师事务所 关于江西天新药业股份有限公司 2024 年度利润分配涉及的差异化分红事项的 法律意见书 致：江西天新药业股份有限公司 3．对于本法律意见书至关重要而又无法得到独立证据支持的事实，本所律 师有赖于有关政府部门、公司或者其他有关单位出具的证明文件及主管部门公开 可查的信息作为制作本法律意见书的依据。 北京市中伦（上海）律师事务所（下称"本所"）接受江西天新药业股份有 限公司（下称"公司"）的委托，根据《中华人民共和国公司法》《中华人民共 和国证券法》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等 法律、行政法规、部门规章、规范性文件及上海证券交易所（下称"上交所"） 相关业务规则（以下统称"适用法律"）的规定，对公司 2024 年度利润分配涉 及的差异化分红事宜（下称"本次差异化分红"）出具本法律意见书。 为出具本法律意见书，本所律师根据适用法律的要求，本着审慎性及重要性 原则对公司提供的与本次差异化分红事项有关的文件资料和事实进行了核 ...